Changes in the Executive Board of Octapharma - Kim Björnstrup, Vice Chairman of Octapharma is leaving the company as of 21.10.20

Changes in the Executive Board of Octapharma - Kim Björnstrup, Vice Chairman of Octapharma is leaving the company as of 21.10.2010
21.10.2010
 
In mutual consent, Mr. Kim Björnstrup has resigned from his position as Vice Chairman of the Octapharma Group with effect as of October 21st, 2010.

Wolfgang Marguerre, Chairman of Octapharma, states: "I appreciate and thank him for his valuable and excellent contribution to our business endeavors throughout the past 18 years. I wish him a successful continuation of his career and good luck for his future."

 

About Octapharma

Octapharma is a biopharmaceutical company. It is dedicated to the safe and optimal usage of human proteins. Octapharma products are state-of-the-art within treatment of haemophilia, immune diseases, volume expansion and plasma transfusions. The company was founded in 1983 and since then has grown to over 4,000 employees. Nowadays it has 37 subsidiaries and representative offices and is making sales in over 80 countries. Turnover in 2009 was Euro 1,008 million.

For more information about the company please click here.

 

Contact:
Octapharma AG
Corporate Communications
Corinne Landolt
Tel.: +41 (55) 451 21 36
Corinne.Landoltanti spam [email protected] spam bot.com

Seidenstrasse 2
CH-8853 Lachen
Switzerland

 

 

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.